Edition:
United States

CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

96.25AUD
6 Dec 2016
Change (% chg)

-- (--)
Prev Close
$96.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,023,475
52-wk High
$121.25
52-wk Low
$95.53

Summary

Name Age Since Current Position

John Shine

69 2011 Independent Non-Executive Chairman of the Board

Paul Perreault

58 2013 Chief Executive Officer, Managing Director, Executive Director

David Lamont

50 2016 Chief Financial Officer

Gordon Naylor

52 2016 President - Seqirus

Greg Boss

54 Group General Counsel, Executive Vice President - Legal and CSL

Karen Etchberger

57 2013 Executive Vice President - Quality and Business Services

Bob Repella

56 2014 Executive Vice President - Global Commercial Operations

Val Romberg

57 2015 Executive Vice President of Manufacturing and Planning

Alan Wills

52 2015 Senior Vice President of Strategy and Business Development

Andrew Cuthbertson

60 2000 Chief Scientific Officer, R&D Director

Laurie Cowan

51 2014 Senior Vice President of Human Resources

Edward Bailey

49 2009 Company Secretary

Megan Clark

57 2016 Director

Tadataka Yamada

71 2016 Director

David Anstice

67 2008 Independent Non-Executive Director

Bruce Brook

61 2011 Independent Non-Executive Director

Marie McDonald

59 2013 Independent Non-Executive Director

Christine O'Reilly

54 2011 Independent Non-Executive Director

Maurice Renshaw

68 2004 Independent Non-Executive Director

Bernard Ronchi

2015 Senior Manager, Investor Relations

Biographies

Name Description

John Shine

Prof. John J Shine, Ph.D, has been an Independent Non-Executive Chairman of the Board of CSL Limited. He was appointed to the CSL Board in June 2006 and became Chairman in October 2011. He is Professor of Molecular Biology and Professor of Medicine at the University of NSW, and a Director of many scientific research and medical bodies throughout Australia. Professor Shine is President of the Museum of Applied Arts and Science (Powerhouse Museum and Sydney Observatory) and was formerly Executive Director of the Garvan Institute of Medical Research. He was also formerly Chairman of the National Health and Medical Research Council and a Member of the Prime Minister’s Science, Engineering and Innovation Council. In November 2010, Professor Shine was awarded the 2010 Prime Minister’s Prize for Science.

Paul Perreault

Mr. Paul Perreault has been Chief Executive Officer, Managing Director and Executive Director of CSL Ltd. He was appointed to the CSL Board in February 2013 and was appointed as the Chief Executive Officer and Managing Director in July 2013. He joined a CSL predecessor company in 1997 and has held senior roles in sales, marketing and operations with his most recent prior position being President, CSL Behring. Mr Perreault has also worked in senior leadership roles with Wyeth, Centeon, Aventis Bioservices and Aventis Behring. He was previously Chairman of the Global Board for the Plasma Protein Therapeutics Association. Mr Perreault has had more than 30 years’ experience in the global healthcare industry.

David Lamont

Mr. David Mark Lamont has been appointed as Chief Financial Officer of the Company., effective 2 January 2016. Mr. Lamont has served as CFO for several leading multi-national public companies across a range of industries since 1999 – including MMG Limited, Oz Minerals Limited, PaperlinX Limited, BHP Billiton’s energy & coal and carbon steel materials divisions, and Incitec Pivot Limited. He is currently CFO and an Executive Director at MMG since 2010. Mr. Lamont served in a number of progressive financial leadership roles in the chemicals and agriculture industries before his appointment as CFO at Incitec Pivot in 1999. He holds a Bachelor of Commerce degree from Deakin University in Australia. Mr. Lamont is a qualified Chartered Accountant and a member of the Institute of Chartered Accountants.

Gordon Naylor

Mr. Gordon Naylor has been re-designated as President - Seqirus of CSL Ltd., effective 2 January 2016. He joined CSL in 1987 and has held many operational and corporate roles in different parts of the CSL Group. Prior to his current role, Gordon was based in the US and responsible for CSL Behring’s global supply chain, the supply of plasma for CSL Behring and CSL’s global information systems.

Greg Boss

Mr. Greg Boss is Group General Counsel, Executive Vice President - Legal and CSL of the Company. He was appointed Group General Counsel in 2009 and is responsible for worldwide legal operations for all CSL Group companies. He joined CSL in 2001, serving as General Counsel for what became the CSL Behring business. In addition to his legal role, Greg is also responsible for overseeing Risk Management for the Group as well as global Communications and Public Affairs. Prior to joining CSL, Greg was Vice President and Senior Counsel for CB Richard Ellis International, after working ten years in private legal practice.

Karen Etchberger

Ms. Karen Etchberger is Executive Vice President - Quality and Business Services of CSL Ltd. She was appointed as Executive Vice President, Quality and Business Services in April 2013 with responsibility for quality, information, technology, logistics, sourcing, enterprise process management, enterprise project management and environment, health and safety. Prior to that, she was Executive Vice President, Plasma, Supply Chain and Information Technology. Karen joined CSL as a Product Manager at JRH Biosciences in 1991 and progressed through a number of positions in technical services, quality management and research and development. Prior to joining CSL, she was Director of Developmental Research at Endotech Corporation.

Bob Repella

Mr. Bob Repella is Executive Vice President - Global Commercial Operations of CSL Ltd., Since July 2014 with responsibility for a variety of global functions including sales, marketing, commercial development and medical affairs. Prior to joining CSL, he held senior management roles at a number of pharmaceutical companies including Cephalon and Wyeth. Bob has over 30 years of commercial experience including biotech and specialty markets.

Val Romberg

Mr. Val Romberg is Executive Vice President of Manufacturing and Planning of the Company. Since January 2015. In 1998 he joined Centeon, a predecessor company of CSL Behring, and has held a broad range of management and R&D positions in the US and Switzerland. During his R&D tenure, CSL Behring had more than 25 product or indication approvals in the US, Europe and Japan. Prior to his current position, Val was Senior Vice President, Global Plasma R&D.

Alan Wills

Mr. Alan J. Wills is Senior Vice President of Strategy and Business Development of the Company. Since February 2015. He is responsible for strategy, portfolio management and business development activities at CSL Behring. Prior to joining CSL, Alan was Executive Vice President, Corporate Development at Auxilium Pharmaceuticals. He was previously head of corporate strategy for Bristol- Myers Squibb and Pfizer, and has worked in strategy and business development roles at United Healthcare and Stanford Medical Center. Alan began his career with the Boston Consulting Group.

Andrew Cuthbertson

Dr. Andrew Cuthbertson is Chief Scientific Officer, R&D Director of CSL Ltd. He was appointed as Chief Scientific Officer and R&D Director in 2000. He is responsible for CSL’s global Research and Development operations. Andrew joined CSL in 1997 as Director of Research. He trained in medicine and science at the University of Melbourne, the Walter and Eliza Hall Institute, the Howard Florey Institute and the National Institutes of Health in the US. Andrew was then a Senior Scientist at Genentech, Inc. in San Francisco.

Laurie Cowan

Ms. Laurie Cowan is a Senior Vice President of Human Resources of CSL Ltd., Since March 2014 and is responsible for leading Human Resources (HR) practices and objectives that focus on talent development, reward systems, culture development and an employee-oriented, high performance culture at the CSL Group of Companies. She previously served as the Head of Human Resources for CSL Behring. Laurie has more than 20 years of HR experience in both the regional banking industry in the US as well as in the pharmaceutical industry globally.

Edward Bailey

Mr. Edward H. Bailey B.Com/LLB, FCIS, is Company Secretary of CSL Limited. He joined CSL Limited in 2000 and had occupied the role of Assistant Company Secretary from 2001. Before joining CSL Limited, Mr. Bailey was a Senior Associate with Arthur Robinson & Hedderwicks.

Megan Clark

Dr. Megan Elizabeth Clark is Director of the Company. Dr Clark is currently a Director of Rio Tinto and a member of the Australian advisory board of the Bank of America Merrill Lynch. She was Chief Executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 to 2014. Prior to CSIRO, she was a Director at NM Rothschild and Sons (Australia) and was Vice President Technology and subsequently Vice President Health, Safety and Environment at BHP Billiton from 2003 to 2008. Dr Clark holds a BSc (Hons) from the University of Western Australia and a PhD from Queen’s University, Canada and is a Fellow of the Australian Academy of Technology and Engineering and a Fellow of the Australian Institute of Company Directors. In 2014, she was appointed a Companion of the Order of Australia.

Tadataka Yamada

Dr.Tadataka (Tachi) Yamada is appointed as Director of the Company., effective from 1 September 2016. He is a US citizen, resident in Seattle, Washington. He is presently a Venture Partner at Frazier Healthcare Partners, a leading provider of growth capital to healthcare companies, a position that he has held since 2015. Prior to this, he was the Chief Medical and Scientific Officer at Takeda Pharmaceuticals, as well as a member of the Board. Dr Yamada has held a range of leadership positions in the health sector, including as President of the Bill & Melinda Gates Foundation Global Health Program and Chairman of Research and Development at GlaxoSmithKline. He currently serves as a director of Agilent Technologies, Inc. and the Clinton Health Access Initiative and a member of the Council of the National Academy of Medicine.

David Anstice

Mr. David W. Anstice BEc, is Independent Non-Executive Director of CSL Limited. He was appointed to the CSL Board in September 2008. He was a longtime member of the Board of Directors and Executive Committee of the US Biotechnology Industry Organisation, and has over 45 years’ experience in the global pharmaceutical industry. Until his retirement in August 2008, Mr Anstice was for many years a senior executive of Merck & Co., Inc., serving at various times as President of Human Health for US/Canada/Latin America, Europe and Asia, and at retirement was an Executive Vice President. He is a Director of Alkermes Plc, Dublin, Ireland, and a Director of the United States Studies Centre at the University of Sydney.

Bruce Brook

Mr. Bruce Robert Brook has been an Independent Non-Executive Director of CSL Limited. He was appointed to the CSL Board in August 2011. He is currently Chairman of Programmed Maintenance Services Limited and a Director of Newmont Mining Corporation. Mr Brook has previously been Chairman of Energy Developments Limited and a Director of Boart Longyear Limited, Lihir Gold Limited and Consolidated Minerals Limited. During his executive career, he was Chief Financial Officer of WMC Resources Limited and prior to that the Deputy Chief Financial Officer of the ANZ Banking Group.

Marie McDonald

Ms. Marie McDonald is Independent Non-Executive Director Director of CSL Ltd. She was appointed to the CSL Board in August 2013. For many years she has practised in company and commercial law and she was a partner of Ashurst (formerly Blake Dawson) until July 2014. Ms McDonald was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia from 2012 to 2013, having previously been the Deputy Chair, and was also a member of the Australian Takeovers Panel from 2001 to 2010.

Christine O'Reilly

Ms. Christine E. O'Reilly is Independent Non-Executive Director of CSL Limited. She was appointed to the CSL Board in February 2011. She is a Director of the Transurban Group, Energy Australia, Medibank Private Limited, Baker IDI and Deputy Chair of Care Australia. Ms O’Reilly has in excess of 30 years financial and operational business experience in domestic and off-shore organisations. During her executive career, she was Co- Head of Unlisted Infrastructure Investments at Colonial First State Global Asset Management and prior to that was the Chief Executive Officer of the GasNet Australia Group.

Maurice Renshaw

Mr. Maurice A. Renshaw is Independent Non-Executive Director of CSL Limited. He was appointed to the CSL Board in July 2004. Formerly, he was Vice President of Pfizer Inc, USA, Executive Vice President, Pfizer Global Consumer Group and President of Pfizer’s Global Consumer Healthcare Division. Prior to his positions in Pfizer, Mr Renshaw was Vice President of Warner Lambert Co. and President of Parke-Davis USA. He has had more than 35 years’ experience in the global pharmaceutical industry with responsibility for R&D, Regulatory, Manufacturing, Finance, Marketing and General Management across Europe, the US and Asia including Japan and China.

Bernard Ronchi

Basic Compensation